NanoDetection Technology™ and Oligomerix™ Announce Exclusive Global Licensing Agreement for Breakthrough Neurodegenerative Diagnostic Antibodies
Publish Date: 2026-06-02 13:30:00
Source Domain: www.businesswire.com
FRANKLIN, Ohio & BRONX, N.Y.–(BUSINESS WIRE)–NanoDetection Technology, Incorporated (NDT) and Oligomerix, Inc. today announced the execution of an exclusive worldwide license agreement. Under the terms of the agreement, NanoDetection has secured exclusive rights to develop and commercialize diagnostic tests utilizing a proprietary panel of nine Tau antibodies discovered by Oligomerix, Inc. and widely recognized for their scientific importance in neurodegenerative disease research. Oligomerix retains rights to therapeutic applications of the antibody panel.
Quantifying Protein State Transitions
The licensed antibody portfolio represents a significant advancement in the characterization of Alzheimer’s disease and other Tau-related pathologies. These highly specialized reagents enable differentiation among distinct Tau species, including cleavage-specific and conformationally altered forms located within the protein filament core.
This degree of specificity provides a foundation for distinguishing Alzheimer’s disease-associated Tau pathology from related neurodegenerative disorders, including Frontotemporal Dementia (FTD), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD), while also enabling quantitative characterization of disease-associated protein aggregation.
NanoDetection has integrated these antibodies into its proprietary TRACE-Tau™ platform, establishing a quantitative framework for monitoring protein-state transitions across the Alzheimer’s disease pathological continuum. The resulting assays are being developed for deployment on NanoDetection’s proprietary Luminorix™ instrument system using the company’s Accuglo™ chemiluminescent assay architecture.
Human Sample Characterization and Translational Validation
Data generated from analyses of multiple Alzheimer’s disease patient samples have demonstrated detection and characterization of aggregated Tau species across a variety of human sample types,…
